Tumor rejection antigens presented by HLA-B44 molecules, and use

Details Tumor rejection antigens presented by HLA-B44 molecules, and use Tumor rejection antigens presented by HLA-B44 molecules, and use

1996-02-20

2000-05-09

Caputa, Anthony C.

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

435 71, 435 721, 435 723, 530328, 436 64, G01N 33574, C07K 706

Patent

active

060602570

ABSTRACT:
Tumor rejection antigens presented by HLA-244 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are derived from MAGE tumor rejection antigen precursors.

REFERENCES:
patent: 5342774 (1994-08-01), Boon et al.
Van der Bruggen et al., "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes On a Human Melanoma", Science 254: 1643-1647 (Dec. 1991).
Khanna et al., "Localization of Epstein-Barr Virus Cytotoxic-T Cell Epitopes Using Recombinant Vaccinia: Implications for Vaccine Development", J. Exp. Med. 176: 169-176 (Jul. 1992).
Parker et al. J. Immunol. 149:3580-3587, Dec. 1992.
Englehard, V.H. Current Opinion in Immunol. 6:13-23, 1994.
Salgaller et al. Cancer Immunol. Immunother. 39(2):105-16 (see abstract), 1994.
Kumar et al. PNAS 87:1337-41, Feb. 1990.

Affiliated with

Also associated with

Rating

Tumor rejection antigens presented by HLA-B44 molecules, and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor rejection antigens presented by HLA-B44 molecules, and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor rejection antigens presented by HLA-B44 molecules, and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1063759